<p><strong>Patients who experience severe neutropenia</strong>: (neutrophil count &lt;0.5 x 109/1 for a minimum of 7 days) or severe peripheral neuropathy, should receive a dose reduction of 20% for subsequent courses (25% for KS patients).<br />
<br />
<strong>Patients with hepatic impairment</strong>: Inadequate data are available to recommend dosage alterations in patients with mild to moderate hepatic impairments. Patients with severe hepatic impairment must not be treated with paclitaxel.<br />
<br />
<strong>Pediatric use</strong>: Paclitaxel is not recommended for use in children below 18 years due to lack of data on safety and efficacy.</p>